Novo Nordisk’s hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

We recently published a list of 10 Stocks Wall Street Is Calling Bullish Amid Market Turmoil. In this article, we are going ...

Novo Nordisk reported results on its next-generation obesity drug in diabetes patients, including data on weight loss that ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest ...

We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to ...

The setback comes at a crucial time for Novo Nordisk, which had positioned CagriSema as its next-generation weight-loss ...

A class action lawsuit was filed against Novo Nordisk A/S (NVO) by Levi & Korsinsky on January 24, 2025. The plaintiffs ...

Novo Nordisk shares rose Monday as the company said it would present new data on the ability of semaglutide, the active ...

Eli Lilly has launched its diabetes and weight-loss drug, Mounjaro, in India, outpacing competitor Novo Nordisk. With ...